1. Home
  2. KG vs CABA Comparison

KG vs CABA Comparison

Compare KG & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KG

Kestrel Group Ltd.

N/A

Current Price

$11.36

Market Cap

225.0M

Sector

Finance

ML Signal

N/A

Logo Cabaletta Bio Inc.

CABA

Cabaletta Bio Inc.

HOLD

Current Price

$2.46

Market Cap

200.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KG
CABA
Founded
N/A
2017
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
225.0M
200.2M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
KG
CABA
Price
$11.36
$2.46
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$13.50
AVG Volume (30 Days)
22.5K
2.6M
Earning Date
11-05-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
8.50
N/A
Revenue
$26,676,137.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.39
N/A
Revenue Growth
1610.20
N/A
52 Week Low
$11.26
$0.99
52 Week High
$36.80
$3.67

Technical Indicators

Market Signals
Indicator
KG
CABA
Relative Strength Index (RSI) 26.80 49.21
Support Level $11.70 $2.32
Resistance Level $14.50 $2.70
Average True Range (ATR) 0.97 0.20
MACD 0.08 0.02
Stochastic Oscillator 5.51 59.42

Price Performance

Historical Comparison
KG
CABA

About KG Kestrel Group Ltd.

Kestrel Group Ltd is specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: